Abstract
Background: Breast cancer is a major cause of death among women worldwide. Treatment for breast cancer involves the surgical removal of cancer tissue, followed by chemotherapy. Although the treatment is efficient, especially when the cancer is detected early, recurrence is common and is often resistant to the previous treatment. Therefore, a constant search for efficient and novel drugs for the treatment of breast cancer is mandatory. Recently, triazole derivatives have shown promising effects against different types of cancer, revealing these molecules as putative anticancer drugs.
Experimental: We have synthesized a series of naphthotriazolyl-4-oxoquinoline derivatives and tested their activity against a human breast cancer cell line. Among the compounds tested, we identified a molecule that killed the human breast cancer cell line MCF-7 with minimal effects on its noncancer counterpart, MCF10A. This effect was seen after 24 hours of treatment and persisted for additional 24 hours after treatment withdrawal. After 1 hour of treatment, the compound, here named 12c, promoted a decrease in cell glucose consumption and lactate production. Moreover, the cells treated with 12c for 1 hour showed diminished intracellular ATP levels with unaltered mitochondrial potential and increased reactive oxygen species production. Additionally, apoptosis was triggered after treatment with the drug for 1 hour. All of these effects are only observed with MCF-7 cells, and not MCF10A. These data show that 12c has selective activity against breast cancer cells and is a potential candidate for a novel anticancer drug.
Results and Conclusion: The naphthotriazolyl-4-oxoquinoline derivatives were obtained in good to moderate yields, and one of them, 12c, exhibited strong and selective antitumor properties. The antitumor mechanism involves inhibition of glycolysis, diminished intracellular ATP levels, induction of ROS production and triggering of apoptosis. These effects are all selective for cancer cells, since noncancer cells are unaffected, and these effects can only be attributed to the whole molecule, as different pharmacophoric groups did not reproduce these effects.
Keywords: Naphthoquinone, Lapachol, 4-quinolone, 1, 2, 3-triazoles, MCF-7, MCF10A.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:A Novel Naphthotriazolyl-4-oxoquinoline Derivative that Selectively Controls Breast Cancer Cells Survival Through the Induction of Apoptosis
Volume: 18 Issue: 17
Author(s): Jessica R. Branco, Vanessa G. Oliveira, Amanda M. Esteves, Ingrid C. Chipoline, Miriam F.O. Lima, Fernanda C.S. Boechat, Fernando C. da Silva, Vítor F. Ferreira, Mauro Sola-Penna, Maria C.B.V. de Souza*Patricia Zancan*
Affiliation:
- Programa de Pos-Graduacao em Quimica, Instituto de Quimica, Universidade Federal Fluminense, Niteroi, RJ,Brazil
- Laboratorio de Oncobiologia Molecular (LabOMol), Departamento de Biotecnologia Farmaceutica, Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, RJ,Brazil
Keywords: Naphthoquinone, Lapachol, 4-quinolone, 1, 2, 3-triazoles, MCF-7, MCF10A.
Abstract: Background: Breast cancer is a major cause of death among women worldwide. Treatment for breast cancer involves the surgical removal of cancer tissue, followed by chemotherapy. Although the treatment is efficient, especially when the cancer is detected early, recurrence is common and is often resistant to the previous treatment. Therefore, a constant search for efficient and novel drugs for the treatment of breast cancer is mandatory. Recently, triazole derivatives have shown promising effects against different types of cancer, revealing these molecules as putative anticancer drugs.
Experimental: We have synthesized a series of naphthotriazolyl-4-oxoquinoline derivatives and tested their activity against a human breast cancer cell line. Among the compounds tested, we identified a molecule that killed the human breast cancer cell line MCF-7 with minimal effects on its noncancer counterpart, MCF10A. This effect was seen after 24 hours of treatment and persisted for additional 24 hours after treatment withdrawal. After 1 hour of treatment, the compound, here named 12c, promoted a decrease in cell glucose consumption and lactate production. Moreover, the cells treated with 12c for 1 hour showed diminished intracellular ATP levels with unaltered mitochondrial potential and increased reactive oxygen species production. Additionally, apoptosis was triggered after treatment with the drug for 1 hour. All of these effects are only observed with MCF-7 cells, and not MCF10A. These data show that 12c has selective activity against breast cancer cells and is a potential candidate for a novel anticancer drug.
Results and Conclusion: The naphthotriazolyl-4-oxoquinoline derivatives were obtained in good to moderate yields, and one of them, 12c, exhibited strong and selective antitumor properties. The antitumor mechanism involves inhibition of glycolysis, diminished intracellular ATP levels, induction of ROS production and triggering of apoptosis. These effects are all selective for cancer cells, since noncancer cells are unaffected, and these effects can only be attributed to the whole molecule, as different pharmacophoric groups did not reproduce these effects.
Export Options
About this article
Cite this article as:
Branco R. Jessica , Oliveira G. Vanessa , Esteves M. Amanda, Chipoline C. Ingrid , Lima F.O. Miriam , Boechat C.S. Fernanda , da Silva C. Fernando , Ferreira F. Vítor , Sola-Penna Mauro , de Souza C.B.V. Maria *, Zancan Patricia*, A Novel Naphthotriazolyl-4-oxoquinoline Derivative that Selectively Controls Breast Cancer Cells Survival Through the Induction of Apoptosis, Current Topics in Medicinal Chemistry 2018; 18 (17) . https://dx.doi.org/10.2174/1568026618666180821142458
DOI https://dx.doi.org/10.2174/1568026618666180821142458 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Structure Activity Relationship Study of N-substituted 3,5-diarylidenepiperidin- 4-ones as Potential Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Cytotoxicity and Anti-inflammatory Activity of Flavonoid Derivatives Targeting NF-kappaB
Recent Patents on Inflammation & Allergy Drug Discovery Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
Current Drug Metabolism REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Prostatic Tumor Stroma: A Key Player in Cancer Progression
Current Cancer Drug Targets Potential Therapeutic Applications of Metal Compounds Directed Towards Hypoxic Tissues
Current Medicinal Chemistry Exploring Photoactivated Disinfection-Induced Bystander Effects on Microbial Biofilms of Aggregatibacter actinomycetemcomitans
Infectious Disorders - Drug Targets Progesterone Receptor Agonists and Antagonists as Anticancer Agents
Mini-Reviews in Medicinal Chemistry SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy
Current Topics in Medicinal Chemistry Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Pictorial US, CT and MRI Findings of Common Hepatic Tumours
Current Medical Imaging Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology
Current Pharmaceutical Design Inhibition of TGF-β Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies
Reviews on Recent Clinical Trials Tumor Specific Novel Taxoid-Monoclonal Antibody Conjugates
Current Medicinal Chemistry Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry Drug Interactions with Normal and TEN Epidermal Keratinocytes
Current Drug Safety Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Changes of Gene Expression in the Developing Brain by Acute Ethanol Exposure
Current Psychopharmacology Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy